Updated:
Regenerex Pharma
Regenerex Pharma is a biotechnology firm advancing regenerative medicine, including PRP and stem cell therapies, with a lead program in osteoarthritis.
Regenerex Pharma
Regenerex Pharma was founded to advance regenerative medicine, a field that uses biological materials to repair or replace damaged tissues. The company's primary focus is on platelet-rich plasma (PRP) and stem cell technologies, which are applied to conditions such as osteoarthritis and chronic wounds. While the firm operates as a publicly traded entity (OTC: RGRX), its structure includes elements of a family office, with founding principals directing capital toward long-term R&D. Investment strategy centers on clinical-stage development, with pipeline candidates that aim to leverage the body's own healing mechanisms. The geographic footprint is primarily U.S.-based, with research and administrative operations likely concentrated in the greater New York area. The firm has not disclosed a total AUM or deployment figure, and its professional headcount is not publicly available. A recent operational milestone includes the company's ongoing work on a Phase 2 clinical trial for its PRP-based osteoarthritis treatment (per public filings, 2023). A structural differentiator is the firm's hybrid status as both a publicly listed entity and a closely held operation, allowing it to access public capital markets while maintaining the strategic focus of a private family office. This dual structure is uncommon among development-stage biotech firms.
General information
Firm type
Family Office
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
—
City
—
Corporate office
—
Sector focus
Frequently asked questions
What is Regenerex Pharma's lead therapeutic program?
Regenerex Pharma's lead program is a platelet-rich plasma (PRP) therapy for osteoarthritis, which has entered Phase 2 clinical trials. The company also explores stem cell treatments for orthopedic and wound-healing indications (per public filings, 2023).
How is Regenerex Pharma structured as a firm?
Regenerex Pharma is publicly traded on the OTC market under the ticker RGRX, but its governance resembles a family office, with capital primarily directed by a small group of founding principals. This hybrid structure allows the firm to raise public funds while maintaining a long-term, research-focused investment horizon.
What investment stages does Regenerex Pharma focus on?
The firm focuses on clinical-stage development, specifically Phase 2 and Phase 3 trials for its regenerative medicine candidates. It does not invest in later-stage commercialization or external ventures.
Does Regenerex Pharma have a published AUM or investment track record?
No, Regenerex Pharma has not publicly disclosed total AUM or deployment figures. Financial information is limited to public filings for its traded stock, which may not reflect the full capital structure of the family office component.
Who are the key principals at Regenerex Pharma?
Publicly available records do not name specific principals beyond board members and executive officers listed in SEC filings. The firm's leadership is not widely disclosed.
What sectors does Regenerex Pharma target?
The firm exclusively targets biotechnology and pharmaceuticals, with a specific focus on regenerative medicine, including platelet-rich plasma (PRP) and stem cell therapies for orthopedic and wound-healing applications.
Does Regenerex Pharma maintain philanthropic structures?
There is no public information indicating that Regenerex Pharma operates a separate philanthropic foundation. The firm's activities appear to be solely commercial and research-oriented.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: